

Diabetes

Lumanity and the PHARMO Institute are partnering to deliver research insights in Diabetes



Disease & Treatment Characterization

- Patient demographics
- Diagnoses and symptoms
- Clinical characteristics
 - BMI
 - Blood pressure
 - Glycemic control [HbA1c]
 - Lipids [LDL, HDL]
 - Continuous glucose monitoring
- Smoking and alcohol consumption
- Complications and comorbidities e.g., cardiovascular disease, obesity, kidney disease

Outcomes, Burden of Disease, & Healthcare Resource Utilization

- Pharmacy (in- & out-patient)
 - Product (including: GLP1, SGLT2, biguanides, sulfonylureas, TZDs, DPP-4 etc.)
 - Date, dosage, quantity
 - Prescriber and costs
 - Adherence/persistence
- Multi-setting healthcare resource use
 - Admissions/discharges
 - Specialist visits (e.g., endocrinologists, ophthalmologist etc.)
 - Procedures
- Mortality

Comparative Effectiveness, Safety, & Tolerability

- Clinical characteristics
 - BMI
 - Blood pressure
 - Glycemic control [HbA1c]
 - Lipids [LDL, HDL]
- Mortality
- Malignancy, pathology
- Social demographics

What makes us different



High patient counts in Diabetes

~352,000 patients with Diabetes

- ~22,000 Type 1
- ~290,000 Type 2
- ~40,000 Unclassified



A unique, longitudinal, and clinically rich dataset

- 2002 onwards (20+ years)
- Ability to follow through multiple healthcare settings
- Data regularly updated and expanded to include new patients and follow-up information

About PHARMO



The PHARMO Institute is an **independent, global leader** in drug safety and outcomes research



The Netherlands has an excellent healthcare system and is a major hub for clinical trials



The **PHARMO Data Network** offers **multi-setting, longitudinal, clinically rich data** with exceptional curation and linkages to hospitals and national registers



Dutch data is **representative of Western Europe** and can be used in global studies as a **robust proxy** or complement to EU-5



As a founding member of SIGMA Consortium, we can access diverse sources of **pan-European real world data (RWD)** on **>100 million patients**



Our capabilities and experience enable us to deliver on a **wide range of real world evidence (RWE) use cases**



⇒ Why choose us?

Luminality can be counted on for service and quality. We utilize proven processes supported by technologically advanced resources to produce high-quality services, with guaranteed satisfaction.